Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Therapy for HIV Patients Failing Previous Therapy

By HospiMedica staff writers
Posted on 02 Oct 2000
In preclinical studies, the non-nucleoside reverse transcriptase inhibitor (NNRTI) capravirine demonstrated a potent antiviral activity against wild-type HIV as well as HIV strains with mutations in reverse transcriptase, such as K103N, that confer broad viral resistance to other NNRTIs to which patients failing treatment may have been exposed. More...


In clinical studies of treatment-naive patients, capravirine showed antiretroviral activity when used alone for a short period of time, and achieved target antiretroviral concentrations in plasma as a part of a combination therapy. A new double-blind 48-week study will evaluate capravirine for use in two groups of HIV-infected patients: those who have never been treated with anti-HIV medications and those who have failed previous treatment. Capravirine, which has been generally well tolerated by patients, was developed by Agouron Pharmaceuticals, Inc. (Toronto, Canada).



Related Links:
Agouron Pharmaceuticals

Gold Member
12-Channel ECG
CM1200B
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Pressure Guidewire
SavvyWire
Half Apron
Demi
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.